
Recce Pharmaceuticals Ltd
ASX:RCE

Intrinsic Value
The intrinsic value of one
RCE
stock under the Base Case scenario is
0.043
AUD.
Compared to the current market price of 0.295 AUD,
Recce Pharmaceuticals Ltd
is
Overvalued by 86%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Recce Pharmaceuticals Ltd
Fundamental Analysis


Revenue & Expenses Breakdown
Recce Pharmaceuticals Ltd
Balance Sheet Decomposition
Recce Pharmaceuticals Ltd
Current Assets | 3m |
Cash & Short-Term Investments | 2.2m |
Receivables | 494.4k |
Other Current Assets | 283.8k |
Non-Current Assets | 1.2m |
PP&E | 1.2m |
Free Cash Flow Analysis
Recce Pharmaceuticals Ltd
AUD | |
Free Cash Flow | AUD |
Earnings Waterfall
Recce Pharmaceuticals Ltd
Revenue
|
9.8m
AUD
|
Operating Expenses
|
-26.5m
AUD
|
Operating Income
|
-16.6m
AUD
|
Other Expenses
|
-1.3m
AUD
|
Net Income
|
-17.9m
AUD
|
RCE Profitability Score
Profitability Due Diligence
Recce Pharmaceuticals Ltd's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

Score
Recce Pharmaceuticals Ltd's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
RCE Solvency Score
Solvency Due Diligence
Recce Pharmaceuticals Ltd's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Score
Recce Pharmaceuticals Ltd's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RCE Price Targets Summary
Recce Pharmaceuticals Ltd
Dividends
Current shareholder yield for RCE is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
RCE
stock under the Base Case scenario is
0.043
AUD.
Compared to the current market price of 0.295 AUD,
Recce Pharmaceuticals Ltd
is
Overvalued by 86%.